Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bouchardy

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2009
Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumorsC Bouchardy, E Rapiti, M Usel, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1996
Multiple primary cancers and estimation of the incidence rates and trendsK Filali, G Hédelin, P Schaffer, et al.
Pharmacogenetics|February 18, 1999
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansG C Ibeanu, J Blaisdell, B I Ghanayem, et al.
Journal of Geriatric Oncology|September 28, 2013
Treatment of breast cancer in the elderly: a prospective, population-based Swiss studyM Joerger, B Thürlimann, A Savidan, et al.
Breast Cancer Research and Treatment|April 14, 2007
Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populationsH M Verkooijen, V C M Koot, G Fioretta, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoinR J Ferguson, S M De Morais, S Benhamou, et al.
British Journal of Cancer|May 30, 2007
Recent increase of breast cancer incidence among women under the age of fortyC Bouchardy, G Fioretta, H M Verkooijen, et al.
Cancer Epidemiology|December 3, 2014
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE projectC A Stiller, A Trama, D H Brewster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Management of women with ductal carcinoma in situ of the breast: a population-based studyH M Verkooijen, G Fioretta, C De Wolf, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2009
Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumorsC Bouchardy, E Rapiti, M Usel, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoinG C Ibeanu, J Blaisdell, R J Ferguson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 1996
Multiple primary cancers and estimation of the incidence rates and trendsK Filali, G Hédelin, P Schaffer, et al.
Pharmacogenetics|February 18, 1999
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in CaucasiansG C Ibeanu, J Blaisdell, B I Ghanayem, et al.
Journal of Geriatric Oncology|September 28, 2013
Treatment of breast cancer in the elderly: a prospective, population-based Swiss studyM Joerger, B Thürlimann, A Savidan, et al.
Breast Cancer Research and Treatment|April 14, 2007
Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populationsH M Verkooijen, V C M Koot, G Fioretta, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoinR J Ferguson, S M De Morais, S Benhamou, et al.
British Journal of Cancer|May 30, 2007
Recent increase of breast cancer incidence among women under the age of fortyC Bouchardy, G Fioretta, H M Verkooijen, et al.
Cancer Epidemiology|December 3, 2014
Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE projectC A Stiller, A Trama, D H Brewster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 16, 2002
Management of women with ductal carcinoma in situ of the breast: a population-based studyH M Verkooijen, G Fioretta, C De Wolf, et al.
Pageof 9